HRP20220760T1 - Metabolički biomarkeri za predviđanje odgovaranja na spoj fgf-18 - Google Patents

Metabolički biomarkeri za predviđanje odgovaranja na spoj fgf-18 Download PDF

Info

Publication number
HRP20220760T1
HRP20220760T1 HRP20220760TT HRP20220760T HRP20220760T1 HR P20220760 T1 HRP20220760 T1 HR P20220760T1 HR P20220760T T HRP20220760T T HR P20220760TT HR P20220760 T HRP20220760 T HR P20220760T HR P20220760 T1 HRP20220760 T1 HR P20220760T1
Authority
HR
Croatia
Prior art keywords
fgf
compound
treatment
subject
proc2
Prior art date
Application number
HRP20220760TT
Other languages
English (en)
Croatian (hr)
Inventor
Christoph H. Ladel
Hans Guehring
Anne-Christine BAY-JENSEN
Morten Karsdal
Per Qvist
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of HRP20220760T1 publication Critical patent/HRP20220760T1/hr

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1825Fibroblast growth factor [FGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/50Fibroblast growth factor [FGF]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/10Musculoskeletal or connective tissue disorders
    • G01N2800/105Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HRP20220760TT 2017-09-29 2018-09-28 Metabolički biomarkeri za predviđanje odgovaranja na spoj fgf-18 HRP20220760T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP17194220 2017-09-29
EP18169324 2018-04-25
EP18782014.7A EP3687558B1 (en) 2017-09-29 2018-09-28 Metabolic biomarkers for predicting responsiveness to fgf-18 compound
PCT/EP2018/076395 WO2019063758A1 (en) 2017-09-29 2018-09-28 METABOLIC BIOMARKERS FOR PREDICTING RESPONSE TO FGF-18 COMPOUND

Publications (1)

Publication Number Publication Date
HRP20220760T1 true HRP20220760T1 (hr) 2022-09-02

Family

ID=63722380

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20220760TT HRP20220760T1 (hr) 2017-09-29 2018-09-28 Metabolički biomarkeri za predviđanje odgovaranja na spoj fgf-18

Country Status (16)

Country Link
US (2) US11513128B2 (https=)
EP (1) EP3687558B1 (https=)
JP (2) JP7791649B2 (https=)
CN (1) CN111163791A (https=)
AU (1) AU2018343982B2 (https=)
CA (1) CA3076029A1 (https=)
DK (1) DK3687558T3 (https=)
ES (1) ES2918250T3 (https=)
HR (1) HRP20220760T1 (https=)
HU (1) HUE058786T2 (https=)
IL (1) IL273613B2 (https=)
LT (1) LT3687558T (https=)
PL (1) PL3687558T3 (https=)
RS (1) RS63293B1 (https=)
SI (1) SI3687558T1 (https=)
WO (1) WO2019063758A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016211950A1 (en) 2015-01-29 2017-07-13 Ares Trading S.A. Immunoassays for high positively charged proteins
IL273613B2 (en) 2017-09-29 2026-02-01 Merck Patent Gmbh Metabolic biomarkers for predicting response to FGF-18 compound
SI3688468T1 (sl) 2017-09-29 2022-08-31 Merck Patent Gmbh Vnetni biomarkerji za predvidevanje odzivov na spojino FGF-18
IL281333B2 (en) 2018-09-10 2025-11-01 Merck Patent Gmbh A method for reducing risk in a clinical trial

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2339002A1 (en) 1996-10-16 2011-06-29 ZymoGenetics, Inc. Fibroblast growth factor homologs
ES2493840T3 (es) 2002-10-07 2014-09-12 Zymogenetics, Inc. Procedimiento de administración de FGF-18
AU2003287697A1 (en) 2002-11-08 2004-06-03 Barnes-Jewish Hospital Uncoupled collagen synthesis and degradation assays
AU2005314438B2 (en) 2004-12-10 2012-03-29 Zymogenetics, Inc. FGF18 production in prokaryotic hosts
US8224579B2 (en) * 2005-06-17 2012-07-17 The Brigham And Women's Hospital, Inc. Method of diagnosing osteoarthritis
US20070292982A1 (en) 2006-06-16 2007-12-20 Jeffery Gail Holloway Method for Manufacturing Transparent Windows in Molded Semiconductor Packages
HRP20120643T1 (hr) 2006-08-25 2012-08-31 Ares Trading S.A. Liječenje poremećaja hrskavice sa fgf-18
JP2009257842A (ja) 2008-04-14 2009-11-05 Ttc:Kk 変形性関節症の検査方法及び診断用キット
JP5762282B2 (ja) 2008-05-02 2015-08-12 インタールーキン ジェネティクス, インコーポレイテッド 変形性関節症に関連する状態に対する遺伝的素因の検出
US20090299769A1 (en) 2008-05-29 2009-12-03 Nordic Bioscience Imaging A/S Prognostic osteoarthritis biomarkers
US20120115137A1 (en) 2010-08-31 2012-05-10 Kornman Kenneth S Methods of Predicting Osteoarthritis
TWI527590B (zh) 2011-06-17 2016-04-01 艾瑞斯貿易公司 Fgf-18之凍乾調配物
AU2013301607B2 (en) 2012-08-06 2018-10-18 Merck Patent Gmbh Prognosis biomarkers in cartilage disorders
CN104736723B (zh) * 2012-08-06 2017-10-31 默克专利有限公司 用于预测对fgf‑18化合物的响应性的遗传标记
US9829493B2 (en) * 2013-07-15 2017-11-28 Steven J. Svoboda Methods and apparatus for assessment of risk for joint injury
CA2931978A1 (en) 2013-12-02 2015-06-11 Abbvie Inc. Compositions and methods for treating osteoarthritis
ES2806026T3 (es) 2013-12-24 2021-02-16 Ares Trading Sa Formulación de FGF-18 en hidrogeles de alginato/colágeno
KR102622290B1 (ko) 2013-12-24 2024-01-05 아레스 트레이딩 에스.아. 크실로글루칸 겔 중의 fgf-18 제형물
HUE040350T2 (hu) 2014-02-20 2019-03-28 Merck Patent Gmbh FGF-18 vegyületadagoló étrend
MX2016010873A (es) 2014-02-20 2016-11-17 Merck Patent Gmbh Factor de crecimiento de fibroblastos 18 en los procedimientos para el trasplante de injertos y para ingenieria de tejidos.
JP6510547B2 (ja) 2014-02-20 2019-05-08 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung Fgf−18を含むインプラント
AU2016211950A1 (en) 2015-01-29 2017-07-13 Ares Trading S.A. Immunoassays for high positively charged proteins
MX380092B (es) 2015-11-06 2025-03-11 Samumed Llc Tratamiento de la osteoartritis.
US9983214B2 (en) 2016-04-15 2018-05-29 Esm Technologies, Llc Method for evaluating articular joint therapeutics
SI3688468T1 (sl) 2017-09-29 2022-08-31 Merck Patent Gmbh Vnetni biomarkerji za predvidevanje odzivov na spojino FGF-18
IL273613B2 (en) * 2017-09-29 2026-02-01 Merck Patent Gmbh Metabolic biomarkers for predicting response to FGF-18 compound
IL281333B2 (en) 2018-09-10 2025-11-01 Merck Patent Gmbh A method for reducing risk in a clinical trial

Also Published As

Publication number Publication date
EP3687558A1 (en) 2020-08-05
JP2020535436A (ja) 2020-12-03
US12332251B2 (en) 2025-06-17
AU2018343982A1 (en) 2020-04-09
US20230251271A1 (en) 2023-08-10
HUE058786T2 (hu) 2022-09-28
US20210231681A1 (en) 2021-07-29
LT3687558T (lt) 2022-06-27
JP7791649B2 (ja) 2025-12-24
WO2019063758A1 (en) 2019-04-04
AU2018343982B2 (en) 2025-03-27
EP3687558B1 (en) 2022-03-16
DK3687558T3 (da) 2022-06-20
PL3687558T3 (pl) 2022-07-18
RS63293B1 (sr) 2022-06-30
ES2918250T3 (es) 2022-07-14
CN111163791A (zh) 2020-05-15
JP2024105273A (ja) 2024-08-06
IL273613A (en) 2020-05-31
CA3076029A1 (en) 2019-04-04
IL273613B2 (en) 2026-02-01
US11513128B2 (en) 2022-11-29
SI3687558T1 (sl) 2022-08-31
IL273613B1 (en) 2025-10-01

Similar Documents

Publication Publication Date Title
HRP20220760T1 (hr) Metabolički biomarkeri za predviđanje odgovaranja na spoj fgf-18
Harvey et al. Intracellular dynamics of hippocampal place cells during virtual navigation
Ito et al. Degradation of soluble VEGF receptor-1 by MMP-7 allows VEGF access to endothelial cells
Ackermann et al. Anti-inflammatory cytokine profile in early human tendon repair
Han et al. Histological scoring method to assess bone healing in critical size bone defect models
Hettrich et al. The effect of mechanical load on tendon-to-bone healing in a rat model
Nahian et al. Histology, periosteum and endosteum
Aronson et al. Sustained proliferation accompanies distraction osteogenesis in the rat
Guenther et al. Comparison of surgically excised premacular membranes in eyes with macular pucker and proliferative vitreoretinopathy
Haubruck et al. The treatment of nonunions with application of BMP-7 increases the expression pattern for angiogenic and inflammable cytokines: a matched pair analysis
Ruppert et al. Histopathological, immunohistochemical criteria and confocal laser-scanning data of arthrofibrosis
Marrero et al. Fibroblast reticular cells engineer a blastema extracellular network during digit tip regeneration in mice
Furuya et al. Bone regeneration for murine femur fracture by gelatin hydrogels incorporating basic fibroblast growth factor with different release profiles
Schwabe et al. A pilot study investigating the histology and growth factor content of human non-union tissue
HRP20220737T1 (hr) Upalni biomarkeri za predviđanje odgovaranja na spoj fgf-18
Vignali et al. Assessing wound vitality in decomposed bodies: A review of the literature
Riamon et al. The earliest tyrannida (Aves, passeriformes), from the Oligocene of France
Ohta et al. The effects of heat on the biological activity of recombinant human bone morphogenetic protein-2
Boesmueller et al. Neurofilament distribution in the superior labrum and the long head of the biceps tendon
Sousa et al. Evaluation of bone turnover markers and serum minerals variations for predicting fracture healing versus non-union processes in adult sheep as a model for orthopedic research
Meyer et al. Keratinization of the esophageal epithelium of domesticated mammals
Kim et al. Methylsulfonylmethane enhances BMP‑2‑induced osteoblast differentiation in mesenchymal stem cells
Granchi et al. Changes of bone turnover markers in long bone nonunions treated with a regenerative approach
Cao et al. Astragaloside-IV induces the differentiation of bone marrow mesenchymal stem cells into osteoblasts through NMUR2-mediated Wnt/β-catenin pathway
Honsawek et al. Elevated serum periostin is associated with liver stiffness and clinical outcome in biliary atresia